The effect of vitamin D supplementation in patients with systemic lupus erythematosus

Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN59058825

Enrollment

Registered

2021-04-12

Start date

2016-11-03

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of vitamin D deficiency/insufficiency in patients with systemic lupus erythematosus Nutritional, Metabolic, Endocrine

Interventions

SLE patients with vitamin D deficiency or insufficiency are supplemented with vitamin D3 8000IU daily for 8 weeks if they are vitamin D deficient, or 8000IU daily for 4 weeks if they are insufficient.

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Fulfills the SLICC classification criteria for SLE 2. Age =18 years 3. The presence of vitamin D deficiency/insufficiency

Exclusion criteria

Exclusion criteria: Patients with stage 4 and 5 chronic kidney disease

Design outcomes

Primary

Measure	Time frame
Systemic lupus erythematosus disease activity measured using SLEDAI-2K at baseline, 6 months and 12 months	—

Secondary

Measure	Time frame
1. Fatigue measured using Fatigue Severity Scale at baseline, 6 and 12 months 2. Interferon signature gene expression measured using quantigene analysis at baseline and 6 months	—

Countries

Malta

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 17, 2026